Complement and protection from tissue injury in COVID-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

1. Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis.International journal of molecular sciences · 2023
   Review
2. Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19.Cell reports. Medicine · 2021
   Article
3. Broad Auto-Reactive IgM Responses Are Common In Critically Ill COVID-19 Patients.Research square · 2020
   Article

Corrections and comments

• Commented on by
  Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort.2020
• Comment on
  Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome.2020
• Comment on
  Home dialysis machine use for emergency dialysis during the COVID-19 pandemic.2020
• Comment on
  Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm.2020

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as